Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that AstraZeneca's zibotentan will become Decision Resources' proprietary clinical gold standard by 2012 and through 2017 for the treatment of metastatic hormone-refractory prostrate cancer due to its competitive advantages in overall efficacy, safety and tolerability and delivery measures over the current gold standard, Sanofi-Aventis' Taxotere. Zibotentan also has a significant advantage in terms of delivery over all current and emerging therapies because it is likely to be used as an oral monotherapy.

"Interviewed key opinion leaders' optimism for zibotentan's Phase II survival data combined with our survey results make zibotentan the most likely agent to supplant Sanofi-Aventis' Taxotere as our gold standard treatment for metastatic hormone-refractory prostate cancer patients," stated Natalia Reoutova, M.Sc., analyst at Decision Resources.

The new report entitled Metastatic Hormone-Refractory Prostate Cancer: Physicians Optimistic About Targeted Therapies also finds that significant differences were observed between U.S. and European oncologists' prescribing patterns, which highlight European oncologists' greater price sensitivity compared to their U.S. counterparts.

About the Report

Metastatic Hormone-Refractory Prostate Cancer: Physicians Optimistic About Targeted Therapies is a DecisionBase 2009 report. DecisionBase 2009 is a decision-support tool that provides in-depth analysis of unmet need, physician expectations of new therapies and commercial dynamics to help pharmaceutical companies optimize their investments in drug development.

The report can be purchased by contacting Decision Resources. Members of the media may request an interview with an analyst.

About Decision Resources

Decision Resources (www.decisionresources.com) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources, Inc. company.

About Decision Resources, Inc.

Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources, Inc. at www.DecisionResourcesInc.com.

All company, brand or product names contained in this document may be trademarks or registered trademarks of their respective holders.

  Natalia Morales                              Elizabeth Marshall   Decision Resources                           Decision Resources, Inc.   781-296-2691                                 781-296-2563   nmorales@dresources.com                      emarshall@dresources.com 

First Call Analyst:
FCMN Contact:

SOURCE: Decision Resources

CONTACT: Natalia Morales of Decision Resources +1-781-296-2691,
nmorales@dresources.com, or Elizabeth Marshall of Decision Resources, Inc.,
+1-781-296-2563, emarshall@dresources.com

Hospital Expansions in Buffalo, N.Y., and Baton Rouge, La., Contribute to Recession Resilience

View Now